サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1445540

前立腺癌生検の世界市場の評価：製品タイプ・ガイダンス・エンドユーザー・地域別の機会および予測 (2017～2031年)

Prostate Cancer Biopsy Market Assessment, By Type, By Product, By Guidance, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 225 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
前立腺癌生検の世界市場の評価：製品タイプ・ガイダンス・エンドユーザー・地域別の機会および予測 (2017～2031年)
出版日: 2024年03月07日
発行: Market Xcel - Markets and Data
ページ情報: 英文 225 Pages
納期: 3～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の前立腺癌生検の市場規模は、2024年から2031年の予測期間中にCAGR 7.74％を記録し、2023年の60億9,000万米ドルから、2031年には110億6,000万米ドルの規模に成長すると予測されています。

世界の前立腺癌生検の市場を形成する要因には、前立腺癌生検へのAIツールの使用、政府の取り組み、キット需要の増加、前立腺リキッドバイオプシーの人気の高まり、MRIガイダンスなどのより安全なガイダンスデバイスの採用などがあります。

世界の前立腺癌生検市場は、進化する医療技術と進化するヘルスケア慣行の反映であるいくつかの重要な要因の影響を受けています。癌識別の精度と有効性を向上させる注目すべき開発の1つは、前立腺癌生検におけるAI技術の利用です。AIシステムは生検画像を正確に分析し、患者の転帰を改善し、誤診の可能性を減らすことができます。

AIツールの活用による需要の拡大

前立腺癌生検の売上は世界で劇的に増加していますが、その主な理由は技術の進歩、特にAI技術の利用です。これらのAI技術は、生検プロセスの精度と一貫性を向上させ、前立腺癌の診断に革命をもたらしています。AIシステムは、複雑な生検画像を分析し、人間の目では見落としてしまうようなパターンやシグナルを検出する能力を有しています。

偽陰性の可能性を減らし、悪性細胞の検出率を上げることで、患者は正確で早期の診断を受けることができます。前立腺癌をより効果的に、より正確に、より低侵襲で特定する方法を提供できるため、前立腺癌生検処置にAIを組み込むことは、腫瘍学における重要な進歩を示し、世界の前立腺癌生検市場の成長と革新に拍車をかける見通しです。

政府の取り組み

前立腺癌啓発キャンペーンや検診プログラムは、世界各国の政府によって積極的に推進されており、これが世界の前立腺癌生検市場の成長に大きな弾みをつけています。これらのプログラムは早期発見に不可欠であり、治療の有効性と生存の可能性を高めます。各国政府は、前立腺癌検診プログラムを支援・促進することで、男性に生検などの早期診断検査を受けるよう奨励しています。より多くの人々が病気の初期段階で診断・治療できるようにするため、このようなイニシアチブは前立腺癌に関連する死亡率の低下に寄与し、世界の前立腺癌生検市場を刺激します。

キット需要の増加

生検キットに対するニーズの高まりが、世界の前立腺癌生検市場の大幅な成長の背景にあります。これらのキットは、前立腺癌の診断に必要な生検において重要な役割を果たしています。その利便性、患者の快適さ、コンプライアンスを向上させる低侵襲診断技術への移行が、需要の増加につながっています。生検キットは医療従事者のプロセスを容易にし、生検の成功と迅速な実施を保証します。

前立腺リキッドバイオプシーの人気の高まり

前立腺リキッドバイオプシーは、世界の前立腺癌生検市場においてますます一般的になりつつあり、これは非侵襲的診断技術への大きな転換を意味します。リキッドバイオプシーは、患者の血液中の循環腫瘍細胞や腫瘍DNAの断片を分析することで、標準的な組織生検よりも侵襲性の低い選択肢を提供します。リキッドバイオプシーは、癌を早期に発見し、その経過を追跡し、治療効果を評価することができるため、広く受け入れられつつあります。

当レポートでは、世界の前立腺癌生検の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の前立腺癌生検市場の展望

  • 市場規模・予測
  • タイプ別
    • 前立腺リキッドバイオプシー
    • 前立腺針生検
  • 製品別
    • 針
    • キット・トレイ
    • その他
  • ガイダンス別
    • MRIガイド下前立腺生検デバイス
    • CTガイド下前立腺生検デバイス
    • 超音波ガイド下前立腺生検デバイス
    • その他
  • エンドユーザー別
    • 病院
    • 診断センター
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 企業別市場シェア

第5章 世界の前立腺癌生検市場の展望：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第6章 市場マッピング

  • タイプ別
  • 製品別
  • ガイダンス別
  • エンドユーザー別
  • 地域別

第7章 マクロ環境と産業構造

  • 需要供給分析
  • 輸出入分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第8章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第9章 規制の枠組みとイノベーション

  • 臨床試験
  • 特許の情勢
  • 規制当局の承認
  • イノベーション/新興技術

第10章 主要企業の情勢

  • 市場リーダー上位5社の競合マトリックス
  • 市場リーダー上位5社の市場収益分析
  • M&A・ジョイントベンチャー (該当する場合)
  • SWOT分析 (参入5社)
  • 特許分析 (該当する場合)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

  • Thermo Fisher Scientific Inc.
  • Becton Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca plc
  • Koninklijke Philips N.V.
  • Biocept Inc
  • Angle plc
  • Eisai Co., Ltd.
  • Onconetix, Inc.
  • StageZero Life Sciences Ltd

第14章 戦略的提言

第15章 当社について・免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 5. Global Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 6. Global Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global Prostate Cancer Biopsy Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 10. North America Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 11. North America Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 12. North America Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 13. North America Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 17. United States Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 18. United States Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 19. United States Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 20. United States Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 23. Canada Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 24. Canada Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 25. Canada Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 26. Canada Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Mexico Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 30. Mexico Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 31. Mexico Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 32. Mexico Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 35. Europe Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 36. Europe Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 37. Europe Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 38. Europe Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 42. Germany Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 43. Germany Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 44. Germany Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 45. Germany Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 46. France Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. France Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 49. France Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 50. France Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 51. France Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Italy Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 55. Italy Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 56. Italy Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 57. Italy Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 60. United Kingdom Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 61. United Kingdom Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 62. United Kingdom Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 63. United Kingdom Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 66. Russia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 67. Russia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 68. Russia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 69. Russia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 72. Netherlands Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 73. Netherlands Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 74. Netherlands Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 75. Netherlands Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. Spain Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 79. Spain Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 80. Spain Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 81. Spain Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 84. Turkey Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 85. Turkey Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 86. Turkey Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 87. Turkey Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Poland Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 91. Poland Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 92. Poland Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 93. Poland Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 96. South America Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 97. South America Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 98. South America Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 99. South America Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Brazil Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 104. Brazil Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 105. Brazil Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 106. Brazil Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 109. Argentina Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 110. Argentina Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 111. Argentina Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 112. Argentina Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 115. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 116. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 117. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 118. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 120. India Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 122. India Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 123. India Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 124. India Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 125. India Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 126. China Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 128. China Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 129. China Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 130. China Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 131. China Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 134. Japan Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 135. Japan Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 136. Japan Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 137. Japan Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 140. Australia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 141. Australia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 142. Australia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 143. Australia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 146. Vietnam Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 147. Vietnam Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 148. Vietnam Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 149. Vietnam Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. South Korea Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 153. South Korea Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 154. South Korea Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 155. South Korea Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 158. Indonesia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 159. Indonesia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 160. Indonesia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 161. Indonesia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 164. Philippines Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 165. Philippines Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 166. Philippines Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 167. Philippines Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 170. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 171. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 172. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 173. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa Prostate Cancer Biopsy Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 178. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 179. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 180. Saudi Arabia Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. UAE Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 184. UAE Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 185. UAE Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 186. UAE Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa Prostate Cancer Biopsy Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Prostate Cancer Biopsy Market, By Volume, In Million Units, 2017-2031F
  • Figure 189. South Africa Prostate Cancer Biopsy Market Share (%), By Type, 2017-2031F
  • Figure 190. South Africa Prostate Cancer Biopsy Market Share (%), By Product, 2017-2031F
  • Figure 191. South Africa Prostate Cancer Biopsy Market Share (%), By Guidance, 2017-2031F
  • Figure 192. South Africa Prostate Cancer Biopsy Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Guidance Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX11089

Global prostate cancer biopsy market is projected to witness a CAGR of 7.74% during the forecast period 2024-2031, growing from USD 6.09 billion in 2023 to USD 11.06 billion in 2031. Factors that shape the global prostate cancer biopsy market include the use of AI tools for prostate cancer biopsies, government initiatives, increased demand for kits, the growing popularity of prostate liquid biopsy and the adoption of safer guidance devices such as MRI-guidance.

The global prostate cancer biopsy market is influenced by several important factors, which are the reflection of evolving medical technology and evolving healthcare practices. One notable development that improves the accuracy and effectiveness of cancer identification is the use of AI techniques in prostate cancer biopsies. AI systems can accurately analyze biopsy images, improving patient outcomes and reducing the likelihood of a misdiagnosis.

In the global prostate cancer biopsy market, government initiatives that provide funding and assistance for developments in cancer diagnosis are crucial to the progress of the field's research and development. The two main objectives of these projects are raising awareness and improving accessibility of enhanced diagnostic instruments.

Additionally, the growing incidence of prostate cancer is driving the demand for biopsy kits, which in turn is propelling the growth of the global prostate cancer biopsy market. These kits make the biopsy process more patient-friendly by enabling less intrusive treatments and providing convenience. Another development is the increasing prevalence of liquid biopsies of the prostate. By analyzing cancer cell DNA in the blood, liquid biopsies provide a non-invasive substitute for traditional tissue biopsies while providing vital tumor information.

Consequently, the precision of biopsies has increased with the use of safer guidance tools, including MRI-guided biopsy devices. With improved visualization of prostate gland made possible by MRI guidance, suspicious regions can be sampled more precisely, reducing biopsy risks. Together, these elements influence the dynamics of the global prostate cancer biopsy market for prostate cancer biopsies, suggesting ways to enhance patient care and diagnostic options.

Philips and imaging biomarker specialist Quibim partnered in October 2023 to introduce the next generation of AI-based imaging and reporting solutions for MR prostate exams. Combining Quibim's AI-enabled image analysis software with Philips' allows physicians to treat prostate cancer patients more quickly and effectively while reducing costs and staffing shortages.

Use of AI Tools to Expand the Demand

Prostate cancer biopsy sales are rising dramatically worldwide, mostly because of advances in technology, especially the use of AI techniques. These artificial intelligence technologies are improving the accuracy and consistency of biopsy processes, which is revolutionizing the diagnosis of prostate cancer. Artificial intelligence systems possess the ability to analyze intricate biopsy images and detect patterns and signals which human eye would overlook.

Reducing the possibility of false negative results and raising the detection rate of malignant cells guarantees that patients obtain accurate and early diagnoses. By providing a more effective, precise, and minimally invasive method of identifying prostate cancer, the incorporation of AI into prostate cancer biopsy procedures marks a significant advancement in oncology and spurs growth and innovation in the global prostate cancer biopsy market.

For instance, a Florida-based medical technology company introduced a cutting-edge AI diagnostic for prostate cancer treatment in April 2023. Doctors are assisted in selecting individualized patient care by ArteraAI's "first-ever predictive test." Patients with localized prostate cancer benefit from being the first of its kind.

Government Initiatives

Prostate cancer awareness campaigns and screening programs are actively promoted by governments across the globe, which has greatly fueled the expansion of the global prostate cancer biopsy market. These programs are essential for early detection and enhance the effectiveness of treatment and their likelihood of survival. Governments encourage men to undergo early diagnostic tests, such as biopsies, by supporting and promoting prostate cancer screening programs. It increases the demand for biopsy procedures and related technology. By ensuring that more people are diagnosed and treated in the early stages of the disease, such initiatives contribute to lowering the death rate related to prostate cancer and stimulate the global prostate cancer biopsy market.

For instance, on 19th November 2023, The United Kingdom Government initiated a significant prostate cancer screening experiment. A screening trial was announced by Prostate Cancer UK and the Government to find ways to diagnose prostate cancer proactively. Thousands of men who are more likely to get cancer were recruited by them. The trial, named TRANSFORM, will use innovative techniques such as magnetic resonance imaging (MRI) screening to discover cases not detected by blood testing and in the absence of cancer symptoms.

Increased Demand for Kits

The growing need for biopsy kits is behind the significant expansion of global prostate cancer biopsy market. These kits play a crucial role in biopsies, which are necessary for the diagnosis of prostate cancer. Their convenience and the move to less invasive diagnostic techniques, which improve patient comfort and compliance, are credited with their increased demand. Biopsy kits facilitate the process for medical professionals, guaranteeing the successful and rapid execution of biopsies. The pattern is part of a larger shift in healthcare that is patient-centric and emphasizes reducing discomfort and increasing diagnostic precision. The global prostate cancer biopsy market is expected to grow significantly as the awareness and prevalence of prostate cancer increase, leading to a rise in demand for these kits.

Co-labeled digital PCR kits are marketed by Stilla Technologies and Atila Biosystems started in March 2023. "naica" is Stilla's primary PCR device, and the kits and assays are made by Atila. The purpose of these digital PCR kits is to identify circulating tumor DNA (ctDNA) in liquid biopsy samples. These samples are obtained from patients with prostate, colon, melanoma, lung, and breast cancer.

Growing Popularity of Prostate Liquid Biopsy

Prostate liquid biopsies are becoming increasingly common in the global prostate cancer biopsy market, which represents a significant shift towards non-invasive diagnostic techniques. Liquid biopsies provide a less invasive option than standard tissue biopsies by analyzing circulating tumor cells or bits of tumor DNA in a patient's blood. The approach is a desirable choice for patients and healthcare professionals because it greatly lowers patient suffering and the chance of problems. Liquid biopsies are becoming more widely accepted due to their ability to detect cancer early, track its course, and evaluate the effectiveness of treatment. The trend highlights the increasing need for better patient-friendly, precise, and effective diagnostic technologies in the management of prostate cancer, which is driving innovation in the global prostate cancer biopsy market.

PanGIA Biotech announced in January 2024 that it aims to develop scalable and real liquid biopsy technology for global impact. It has completed its prospective, multicenter, three-year clinical study on liquid biopsy for prostate cancer and the study was conducted prospectively. The news was announced as the business got ready to start more clinical trials with the PanGIA Liquid Biopsy Platform for early multi-cancer diagnosis.

North America Dominates the Market

The global prostate cancer biopsy market is dominated by North America, which is a result of several important factors. Firstly, the area is home to a highly developed healthcare infrastructure with a focus on cancer research and diagnostics, which is made possible by significant expenditure on medical technology. The population's high level of knowledge of prostate cancer and the value of early detection plays a significant role in the high demand for biopsy procedures.

Also, the strong regulatory environment and pro-innovation policies in healthcare in North America aid in the quick uptake of cutting-edge diagnostic tools like AI-enhanced imaging and MRI-guided biopsies. When assessed together, these factors guarantee North America's dominant position in the industry, propelling advancement and establishing global benchmarks for prostate cancer diagnosis.

Oxford BioDynamics, plc announced in September 2023 that its EpiSwitch Prostate Screening (PSE) blood test has been validated in its US clinical laboratory. It means men who are at risk of prostate cancer can immediately access their highly accurate PSE test.

Future Market Scenario (2024 - 2031F)

The global prostate cancer biopsy market is expected to be significantly impacted by the excessive adoption of AI tools. The market is to be benefited from the increasing accessibility of the technology in the future.

The rising demand for minimally invasive procedures, such as liquid biopsies, will significantly propel the growth of the market in the future. Liquid biopsy requires less time and delivers precise results.

The need for biopsy techniques and diagnostic technology may rise significantly in various countries in Asia, Africa, and Latin America due to rising access to healthcare facilities and upgrading healthcare infrastructure. The growth will positively impact the global prostate cancer biopsy market in the future.

Healthcare professionals are actively adopting numerous screening techniques like active surveillance and tailored screening which will boost the growth of the global prostate cancer biopsy market in the future.

Key Players Landscape and Outlook

Major firms in the global prostate cancer biopsy market are engaging in collaborations. It is a strategy that greatly boosts growth and innovation in the global prostate cancer biopsy market. Companies can make use of each other's advantages through these collaborations, which frequently involve sharing technology breakthroughs, research capacity, and market access. Partnerships may result in the creation of less intrusive, more precise biopsy technologies, improving patient care and diagnostic accuracy. To increase detection rates, technology businesses and biopharmaceutical companies should form partnerships to expedite the integration of AI and machine learning in biopsy analysis. In addition to advancing technology, these joint initiatives broaden the application of cutting-edge diagnostic tools and provide a cooperative yet competitive market environment that benefits patients everywhere.

Following the successful evaluation of a blood-based genomic profiling test in prostate cancer, MBdx and AstraZeneca extended their collaboration agreement in June 2023 to support the shift from tissue to liquid biopsy. With the help of the PROSPER 2.0 project's AlphaLiquid HRR test, patients with metastatic castration-resistant prostate cancer (mCRPC) now have a plethora of options.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Prostate Cancer Biopsy Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
    • 4.1.2. By Volume
  • 4.2. By Type
    • 4.2.1. Prostate Liquid Biopsy
    • 4.2.2. Prostate Needle Biopsy
  • 4.3. By Product
    • 4.3.1. Needles
    • 4.3.2. Kits and Trays
    • 4.3.3. Others
  • 4.4. By Guidance
    • 4.4.1. MRI-Guided Prostate Biopsy Devices
    • 4.4.2. CT-Guided Prostate Biopsy Devices
    • 4.4.3. Ultrasound-Guided Prostate Biopsy Devices
    • 4.4.4. Others
  • 4.5. By End-user
    • 4.5.1. Hospitals
    • 4.5.2. Diagnostic Centers
    • 4.5.3. Others
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia-Pacific
    • 4.6.4. South America
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Prostate Cancer Biopsy Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. By Value
      • 5.1.1.2. By Volume
    • 5.1.2. By Type
      • 5.1.2.1. Prostate Liquid Biopsy
      • 5.1.2.2. Prostate Needle Biopsy
    • 5.1.3. By Product
      • 5.1.3.1. Needles
      • 5.1.3.2. Kits and Trays
      • 5.1.3.3. Others
    • 5.1.4. By Guidance
      • 5.1.4.1. MRI-Guided Prostate Biopsy Devices
      • 5.1.4.2. CT-Guided Prostate Biopsy Devices
      • 5.1.4.3. Ultrasound-Guided Prostate Biopsy Devices
      • 5.1.4.4. Others
    • 5.1.5. By End-user
      • 5.1.5.1. Hospitals
      • 5.1.5.2. Diagnostic Centers
      • 5.1.5.3. Others
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
      • 5.1.6.1.1. By Value
      • 5.1.6.1.2. By Volume
      • 5.1.6.2. By Type
      • 5.1.6.2.1. Prostate Liquid Biopsy
      • 5.1.6.2.2. Prostate Needle Biopsy
      • 5.1.6.3. By Product
      • 5.1.6.3.1. Needles
      • 5.1.6.3.2. Kits and Trays
      • 5.1.6.3.3. Others
      • 5.1.6.4. By Guidance
      • 5.1.6.4.1. MRI-Guided Prostate Biopsy Devices
      • 5.1.6.4.2. CT-Guided Prostate Biopsy Devices
      • 5.1.6.4.3. Ultrasound-Guided Prostate Biopsy Devices
      • 5.1.6.4.4. Others
      • 5.1.6.5. By End-user
      • 5.1.6.5.1. Hospitals
      • 5.1.6.5.2. Diagnostic Centers
      • 5.1.6.5.3. Others
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. Asia-Pacific
    • 5.3.1. India
    • 5.3.2. China
    • 5.3.3. Japan
    • 5.3.4. Australia
    • 5.3.5. Vietnam
    • 5.3.6. South Korea
    • 5.3.7. Indonesia
    • 5.3.8. Philippines
  • 5.4. South America
    • 5.4.1. Brazil
    • 5.4.2. Argentina
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type
  • 6.2. By Product
  • 6.3. By Guidance
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Demand Supply Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Thermo Fisher Scientific Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Becton Dickinson and Company
  • 13.3. F. Hoffmann-La Roche Ltd.
  • 13.4. AstraZeneca plc
  • 13.5. Koninklijke Philips N.V.
  • 13.6. Biocept Inc
  • 13.7. Angle plc
  • 13.8. Eisai Co., Ltd.
  • 13.9. Onconetix, Inc.
  • 13.10. StageZero Life Sciences Ltd

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer